News, Discoveries, and Updates

You can read our latest newsletter about World Glaucoma Week by following this link.

Thank you for this opportunity, Doctor. What are your thoughts on the longevity field?

First of all, I'm glad that there is one. When I was a med student back in the 80s, aging was not only considered unavoidable but also "normal" or "natural". If someone was over 80 and dying without a “disease that had a name” then the cause of death was "natural causes".
 
Did that bother you?

Yes, and even more so that some of my professors seemed to try less to help older patients, as if "their time had come" or something. I couldn't accept that we all are like having a time bomb inside us and "when the time comes", we will have to die, and there is nothing we can do about it. Not to mention the constant decline of our capabilities as age progresses.
 
Why? Don't things get older as time passes and eventually break?

You see? This is always my disagreement. We are not "things" like the walls of a house that undergo wear and tear from the elements and their paint chips away or their surface deteriorates. Or like an old car that gets rusty. We are living organisms, and we inherited the ability to repair ourselves constantly. Most of our cells are constantly replaced with new ones. Even our entire blood is replaced every 4 months.

You are an eye surgeon; are the cells of the eyes replaced by new ones?

The "official" answer that any ophthalmologist will give you is that cells, such as the cells on the surface of the cornea, are regularly replaced. However, some other cells, such as certain nerve cells in the retina, may have limited ability to regenerate or none at all. That's the old school of thought.

You mean that nerve cells can be regenerated too?

Definitely.

With a drug or a surgical procedure?

The only tool powerful enough to do so is gene therapy. Everything in a living organism—how it looks, how it acts, how it heals—is controlled by its genes. Small molecules and such can't have such an impact. You have to manipulate the genes, and thankfully, this is the era in which we are able to do so to our advantage.

From your answer, I'm guessing that you are not a huge fan of vitamins and supplements.

Well, you said it yourself: supplements. All these have meaning if you are deficient in something; then you should definitely get a supplement to treat your deficiency. And if you overdo it, it will definitely have side effects. In any case, no supplement or vitamin will extend your life. The same goes for most of the interventions that I'm constantly hearing about. Sleep, exercise, proper diet will help you, but there is no way they will extend your life beyond what people accept as the limit to human life. The only tool powerful enough to do that, and I could also say meaningful, is gene therapy.

People often perceive gene therapies as something exotic.

Actually, I think not many people have even heard of gene therapies or know what they are. The reason is that so far, gene therapies are targeting rare inherited monogenic diseases that too few people have heard of. This is something that has to change, and that is one of the reasons that we founded GENORASIS. Not only do we want to help as many people as possible by targeting more common diseases, but we also want to get the word out there and popularize those treatments. People have to know that they exist and that they are powerful enough to cure conditions that we thought were incurable.

Tell us about GENORASIS and what exactly you are trying to achieve.

We founded GENORASIS last year with Liz Parrish with two main tasks in mind. First, to help as many people as we can, starting with a disease that is considered incurable and affects millions worldwide. Second, to make gene therapy more widely known to people, with all the implications that entails: encouraging more people to seek those treatments and making the prices, which are currently high, more affordable. Additionally, in my opinion, there is a necessary step before achieving the ultimate cure for aging: curing some of the diseases that come with age. For our first target, we chose the decline of the optic nerve, the cable that connects our eyes with our brain, which occurs unavoidably with aging, as well as a silent disease that leads much earlier to blindness called glaucoma. Glaucoma affects about 100 million people worldwide, and the weakening of the optic nerve that comes with age affects all of us.

And you have a cure for that? To actually restore vision to blind people?

We have an enhanced gene therapy that can be delivered to the eye through a safe, fast, and simple procedure. We have preliminary results from scientists, and we have a deep understanding of why that works, but we have to follow all the intermediate steps to get the actual cure to human patients. That includes a proof of concept study in animals, followed by a process to get into clinical trials, and then approval from the FDA.

How long would that take?

It is a fairly quick process for such an important task. I don't want to commit to specific numbers in this interview, but the FDA has The Accelerated Approval Pathway. They aim to facilitate efforts like ours that will offer a breakthrough over current treatments, where you can get approval significantly earlier than the end of the clinical trials if the treatment shows definite improvement in patients.

What do you need to succeed?

Like in any breakthrough, you need two things: a great team and money to finance the research. We have the best team possible for such a mission. People who have dedicated their lives to fighting aging and aging-related diseases, who understand the importance and the pressure of time. I'm honored to have such renowned scientists like Bill Andrews and Aubrey DeGrey on our team, and of course Liz, whose restless passion and courage make all of this possible. As for money, you always have to remind investors of the importance of our mission.

Don't they know it?

Investors may have some awareness of our mission, but it's crucial to continually emphasize its significance and potential impact. Our cure has the potential to be very profitable in addition to its profound societal benefits.

Could it have other applications?

Many. The purpose of this specific gene therapy is nerve regeneration and neuroprotection of nerves of the central nervous system. Apart from the optic nerve and glaucoma, it could help regain function and movement in people with spinal injuries and even some cases of hearing loss. The possibilities are endless, and the audience it addresses is very broad.

Do you have a final comment to end our interview?

Since we are on the topic of investors, and without wanting to diminish the significance of other investments, I believe that fighting aging and age-related diseases is the most important of all possible investments. By investing in companies like ours, you buy time and function. If you live longer and in good health, and are able to see, hear, and move, then you can pursue any other endeavors you desire.

Thank you, Doctor Papazoglou.

It was my pleasure.

Nothing is more important than health for an individual, but here we don't just talk about health problems, but also function. Being able to see, walk, and hear—all functions controlled by our central nervous system. People with severe visual problems would give anything to regain sight, just as those with mobility limitations would do anything to regain the ability to walk. Because of that, investing in regenerative medicine and gene therapies not only makes a difference in people's lives but also positions you for financial success.

Ask for more information and we will send you our basic material for your review.

Doctor Niko Papazoglou M.D., an experienced eye surgeon and the CEO and co-founder of GENORASIS™, sheds light on the significance of World Glaucoma Week and urges investors to seize the opportunity to invest.

During World Glaucoma Week, our focus intensifies on the urgent need for innovative solutions to combat this silent thief of sight and the inevitable weakening of vision that comes with age.

As we raise awareness about the impact of glaucoma on millions worldwide, we also highlight the tremendous opportunity for investors to join us in pioneering breakthroughs in gene therapy for optic nerve regeneration.

Together, we have the power to transform lives, restore vision, and drive lucrative returns on investment. Join us in the fight against glaucoma and secure a brighter future for all.

Liz Parrish, MBA, COO, and co-founder of GENORASIS™, stands as one of the most prominent figures in the global longevity community. As the first human to receive gene therapies to treat the effects of aging, she urges investors to direct their attention
towards combating aging diseases.

Why longevity? In prioritizing longevity, we are acknowledging the profound impact that extending our lifespans can have on our ability to witness and participate in the unfolding of technological advancements.

By prioritizing our health and well-being, we ensure that we have the opportunity to experience the full spectrum of innovations that humanity is poised to achieve. From breakthroughs in artificial intelligence to advancements in space exploration, the journey of technological evolution is one that we aspire to witness in its entirety.

Therefore, embracing longevity becomes not just a personal goal but a collective endeavor to maximize our potential and contribute to the future of technological progress.

INNOVATING FOR BETTER THERAPIES: HOW A GENE THERAPY COMPANY IS TRANSFORMING HEALTHCARE

Gene therapy has seen immense progress in recent years, and one company is leading the charge.
GENORASIS™ is leveraging groundbreaking advancements in research and development to produce innovative and unique therapies with the aim of transforming healthcare.
From utilizing cutting-edge technology and partnering with leading scientists to investing heavily in research and development, this company is pushing the boundaries of healthcare.
As a result of these efforts, GENORASIS™ would soon be able to introduce novel therapies that can be used to effectively treat a wide range of ocular diseases and health conditions of Central Nervous System.
GENORASIS™ has the ability to develop treatments that are more effective and efficient than traditional methods and drastically improve the quality of healthcare globally. In addition, our therapies could reduce the overall cost of healthcare and health insurance, making it more accessible to those who need it most.

Embarking on a Transformative Path: Our Proof of Concept Study

Our Proof of Concept study is meticulously outlined and poised to usher in a new era of medical breakthroughs.
This study aims to unlock the potential of regenerating damaged axons of neurons, offering a ray of hope to individuals who have suffered vision loss due to glaucoma, neuritis, or optic nerve injuries.
Our optimism extends beyond ocular conditions – we believe this method holds promise for treating a range of peripheral nerve disorders, including spinal injuries.
As we stand on the threshold of this transformative endeavor, we extend an invitation to visionary investors who dare to dream alongside us.
By completing our investor's form, you can become an integral part of the journey toward groundbreaking solutions for vision restoration and the advancement of medical science.

GENORASIS in Focus: A Snapshot Q&A with the Founders

Q: Mrs. Parrish, as a pioneer in the longevity community, how crucial is good vision in the context of achieving extreme longevity?
L.P.: Vision plays a crucial role in overall well-being and quality of life as we age. Maintaining good vision allows individuals to engage in daily activities, stay independent, and enjoy a higher quality of life. Poor vision, on the other hand, can lead to limitations, reduced mobility, and a greater risk of accidents and falls. By preserving and enhancing vision health, we contribute to a longer and more fulfilling life.
Q: What inspired you to address the challenge of glaucoma and vision loss?
L.P.: Sight is an invaluable gift that millions of people lose to glaucoma. In response to this pressing challenge, I set out to assemble an exceptional team to address this condition.
GENORASIS emerged as the clear answer, with groundbreaking gene therapy offering hope and potential for vision restoration. 
Q: Doctor Papazoglou, what motivated you to undertake the challenging mission of seeking a cure for glaucoma through gene therapy?
N.P.: In my 25 years as a doctor, I've seen the devastating impact of glaucoma on thousands of people. It can slowly steal a person's vision without any noticeable symptoms until it's too late. I've seen the frustration and despair in my patients' eyes when they learn that the damage caused by glaucoma cannot be reversed. I am a strong supporter of the power of gene therapy and I believe it has the potential to revolutionize glaucoma treatment and offer a ray of hope to those affected by this condition.

OUR CO-FOUNDER LIZ PARRISH SET TO INSPIRE AT LONGEVITY SUMMIT DUBLIN 2023.

We are thrilled to share the exciting news that our co-founder, Liz Parrish, will be a distinguished speaker at the upcoming Longevity Summit, scheduled to take place from August 17th to 20th, 2023, in Dublin. This premier event gathers thought leaders, experts, and innovators from across the globe to explore cutting-edge advancements and insights in the field of longevity and healthspan.

Mark your calendars for August 19th, as Liz takes the stage to share her profound insights on longevity and nerve regeneration. With a deep-rooted passion for promoting healthy living and a profound understanding of gene therapy, her talk promises to be a highlight of the summit.

© 2024 GENORASIS™   -   All rights reserved